{"name":"Insulet Corporation","slug":"insulet","ticker":"PODD","exchange":"NASDAQ","domain":"insulet.com","description":"Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is ","hq":"Acton, MA","founded":0,"employees":"5400","ceo":"Jim Hollingshead","sector":"Medical Devices / Diabetes Technology","stockPrice":151,"stockChange":2.16,"stockChangePercent":1.45,"marketCap":"$10.5B","metrics":{"revenue":2900800000,"revenueGrowth":33.9,"grossMargin":71,"rdSpend":301100000,"netIncome":247100000,"cash":907200000,"dividendYield":0,"peRatio":35.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Insulet Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Insulet reported revenue of $1.1 billion for the full year 2023, a 24% increase from the previous year.","drugName":"","sentiment":"positive"},{"date":"2023-11-21","type":"deal","headline":"Insulet to Acquire Companion Medical","summary":"Insulet has agreed to acquire Companion Medical, a company that develops and manufactures insulin management systems.","drugName":"","sentiment":"positive"},{"date":"2023-09-15","type":"regulatory","headline":"FDA Approves Omnipod 5 System","summary":"The FDA has approved the Omnipod 5 System, a hybrid closed-loop insulin pump system designed for people with type 1 diabetes.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9zVHpBbjVSWEFucFAzTWxzMWVpcjFmU3JzWW0xbFdYeTNGYi1PZjRnNjZ6TDlGeEVoR3BNeTFMY0hyUU5aZmQwSmtGTk5KdTlQRXRQbmREQTYzMUNWblHSAWNBVV95cUxNVkdrWUloN0Y4QjRJVTVEYVc1cFhReGlDc1BONkltR18yLXZIWTJXa1NocVU5LXJ6M0JXa2lwaG9NVFZBdndXWS1ud2RzVHBWOVdYODZ3bl9GcmNOZnlTNVpsY3c?oc=5","date":"2026-03-21","type":"pipeline","source":"Bitget","summary":"Is Insulet's Stock Lagging Behind the Dow? - Bitget","headline":"Is Insulet's Stock Lagging Behind the Dow?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOd1RkVi1CcThaME0wY2tkaG5NN3ZGYllYaHRzb21MUWNvV0ZqUGN0emF6N3A4OUQtbEtyUFFCLWxFTXhzXzRoNEJCbkxmaUUwWFJ0azQ3cFRHdUFjSGRQRlQxQmdwUTFGaTFvcHUwMnZUMTBhM2J3N1ZwcHRPM05KLU1kNExqczBPeU1vd01tZGlRQmg2UUcyeWt4VFhIZWM3Y3I2QUJXSXlaOWlpSUc2MURSWl9wdnNxOVZrYUpEdXpXNFQzQ1FpTA?oc=5","date":"2026-03-13","type":"pipeline","source":"Reuters","summary":"Insulet recalls some insulin devices in US over leakage risk - Reuters","headline":"Insulet recalls some insulin devices in US over leakage risk","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQWkh5M1lxRGNUNFlzVG4xTjBvT2g2d3B5N0VYNVNYbFppOTVSaGtPUDM5RWJhWU9senNxVl9JSUQzN3c4UXB5OFZYMElvMjltZUpEczlmbUZNMnJZR3A0bmI2X2hzSXZRWkpiZlZIeEo2dGFVVi1CT05jZ0NrYXRwd1ZPWVJFN2tKZ0p4UzJiTExEZDNGLVBkTHYzVWE0RXBWS3lYc2ktQ0tlbFdSSk1IT0U2ME8wclgwMmNOUzVOYVFLYnBrZkI0NEpfUktVU2otMExGV3BqeTBvd1pnOWFxQzVhRWI3OElkcFk5cWMwRnBmdWNCQWQ1dlJTUzFFcHJrYm1ibEQ5Q0JHLUlfN0pHbEdfUy1TdE1PYmJoYmw1cUM?oc=5","date":"2026-03-04","type":"pipeline","source":"PR Newswire","summary":"Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO - PR Newswire","headline":"Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPZDllaTFjeWhEYm1vQ1NPSDI2aGlWM2Znc09VMkZQeFlLcGdvV25LYUdERlh4SnpDT1VwUEo1X0ZqNUVRY3loLV9rQ25JRHVxNUk2V2Y1NU9OMmxYTGdHNkVTcmRaMkFReTRHU2Fsak85UTFpZFJXdzQ1bVpvTENOQ1pLMkhxUjd2VG03Ng?oc=5","date":"2026-03-04","type":"pipeline","source":"The Business Journals","summary":"Mass. biotech giants added workers in 2025 despite industry-wide layoffs - The Business Journals","headline":"Mass. biotech giants added workers in 2025 despite industry-wide layoffs","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOU0JPSVJ2S3lsd21CRjdPN2o2cVJTXzF2ZkkxZ09ZXzZWYjVUODk5S1VHeWlwYUVUWUFicno2WW1kNlNFdjV4ZW5hLVJQdEt4cFFPQ18wLWhET2oybXJ0NUk2TmI1WEwxZWNiakJhMHBoOFdteUhCZWZpVHRzNXlvMm4zeUJzQQ?oc=5","date":"2026-02-23","type":"pipeline","source":"Quiver Quantitative","summary":"Insider Stock Purchases: February 23, 2026 - Quiver Quantitative","headline":"Insider Stock Purchases: February 23, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPQndacTJjQ2Z1VnF5Yzlic1BpSlhUME03eFhxbGZlUnJGckQzRVJjSmlscEduRnpDYjVBM0c5LUU2UW1aNnJUcGVyN0lnb0FmalFHQU9Kd3ZxdkNoTl9reTV3ek1fd2htZnplSFJTSmthSlNCaWFFYWZNSG1zNW9IZmhUYw?oc=5","date":"2026-02-23","type":"pipeline","source":"Yahoo Finance","summary":"O5 Adoption Leads to Bullish Views Around Insulet Corporation (PODD) - Yahoo Finance","headline":"O5 Adoption Leads to Bullish Views Around Insulet Corporation (PODD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOMjdlRUFCOVViRzJIZnlaVGNqMUdYMkpPSlNhMU9qand2ODBSUmF2bGN2UXN2cWo5cDFGck00QjVLVGNWek1NbjJfeDFIaVY4NXBwNVRiQ1NNODJWR19GTW5HMmJCQ3E2MnlTSEVoYlMySWJVYmRBX05zVThVZkhoaUt3azVWeXphdDFsOTJBSmw3MmIwdmZXOUhJTmI3U25lWGNCRm9oM2s1MzhxazliakdEM2E?oc=5","date":"2026-02-19","type":"earnings","source":"Seeking Alpha","summary":"Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations (NASDAQ:PODD) - Seeking Alpha","headline":"Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations (NASDAQ:PODD)","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-02-18","type":"earnings","source":"AlphaStreet","summary":"Insulet Corporation Reports 31% Annual Revenue Growth; Authorizes $350 Million Repurchase Increase - AlphaStreet","headline":"Insulet Corporation Reports 31% Annual Revenue Growth; Authorizes $350 Million Repurchase Increase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPSXFNUl9la2VaQjVrU0tRR0ZZQ2hGWXJlUm1rTkR2cHFKSnBhTXRKWU1aQk9kTmtBbUE4MWZYQlE4NWdpR3pjVlhmeV9UVGN0eHY0OThHOVhLdlpjeWc2SkdPUGtra21UMThSTExxZnBsSDZsZ2pvVFF5TkRMbjZNcEpxMkRLV1RBU29kNzRrWmNSanhkZWo2R2ZHTFE0bVJjejF2U19NNFNLS21ia1J2X2ZQQ3RXMFV6LTBteVhKRExWZ2JaYUhiNWE1cUFmTU14OTFXUk1tcE9MSVZRLUFEYTFhZy1ZOF9SN0dYN0ZHajZnZjJKZWl6dDhBME1VUQ?oc=5","date":"2026-02-18","type":"earnings","source":"The Chronicle-Journal","summary":"Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues - The Chronicle-Journal","headline":"Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues - The Chronicle","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNM3Y2QjhFX0dteURDZ0hLM1YtVFV5Y3hieWwwejA4TkFXVTJOTFJZdjk1bnQtVEJsS2VOZDJXcnIwXzN6c3hRaUNXTnZkVFJWb2tKaVgwZVh2a25uRVd4LVBCQ0xSelRqMHEtQngtd04xNXVMeVdYcEIxU3dnYVN4bkFlb0lBQUhpSDFCMHhxWU5kQjlNeGxKNm9iN2JCTVVRaXFGc2ZVRG9Td3lqMG1F?oc=5","date":"2025-09-18","type":"pipeline","source":"Fierce Pharma","summary":"Insulet enlists Pantone for color-focused push to make Omnipod pump the pick of the bunch - Fierce Pharma","headline":"Insulet enlists Pantone for color-focused push to make Omnipod pump the pick of the bunch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPelF5aVBvNTFHN0V2S1QyOUthSzhfdkhWMWZnTEZfWDZwczQzMjNYUHJmMlVaQUN0YUxwMWVIX2RVc1BmN2k0SXV0ZzVaQ0hxR3diYjNDZ0w0UFRZcVN0cUxMN05ZbWxudlpJS3BDOUR0X2dRQkV3RzRTOS1SQldMN3FZWHgzWk5GOElBR2R0a3REUWtUSWIxUFhWYWNoYndPVndEVkxTOEd6bFE4N29IeXlUdzh1MEF0SVM2cXFoU0poWDdrYTBEREN0TTR5Z2NQVjhCS0pR?oc=5","date":"2025-09-16","type":"pipeline","source":"Reuters","summary":"Medical device maker Insulet taps industry veteran Flavia Pease as CFO - Reuters","headline":"Medical device maker Insulet taps industry veteran Flavia Pease as CFO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOV3ptTnlKZWV3cWlqSEUzWmFmMm5ybUhSbVg3VHpjQ2JZRHA4d2J0cUxyQ3VKS3BJTllLQ0otR2JBQXFCbi0zeV9sMXdvWGRMRVVnb1cwd0dnMEVUajVQYldfM1IyTUhCWlhOZWN2YW11YUE5ak54aE9qNEtuamYzaUE1WVh5QzMzbTVVSEFBbks2TENOdXAtaXRjVHpMQVN6Zi13LTFTNFFkWFU?oc=5","date":"2025-08-13","type":"earnings","source":"Seeking Alpha","summary":"Insulet’s Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold (PODD) - Seeking Alpha","headline":"Insulet’s Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold (PODD)","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Medtronic","Tandem Diabetes Care","Roche Diabetes Care"],"therapeuticFocus":["Diabetes Technology"],"financials":{"source":"sec_edgar+yahoo","revenue":2708100000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":2708100000,"period":"2025-12-31"},{"value":2071600000,"period":"2024-12-31"},{"value":1697100000,"period":"2023-12-31"},{"value":1305300000,"period":"2022-12-31"},{"value":1098800000,"period":"2021-12-31"},{"value":904400000,"period":"2020-12-31"}],"grossProfit":1939900000,"grossProfitHistory":[{"period":"2025-12-31","value":1939900000},{"period":"2024-12-31","value":1445700000},{"period":"2023-12-31","value":1159900000},{"period":"2022-12-31","value":805600000}],"rdSpend":301100000,"rdSpendHistory":[{"period":"2025-12-31","value":301100000},{"period":"2024-12-31","value":219600000},{"period":"2023-12-31","value":205000000},{"period":"2022-12-31","value":180200000}],"sgaSpend":1165000000,"operatingIncome":473800000,"operatingIncomeHistory":[{"period":"2025-12-31","value":473800000},{"period":"2024-12-31","value":308900000},{"period":"2023-12-31","value":220100000},{"period":"2022-12-31","value":37600000}],"netIncome":247100000,"netIncomeHistory":[{"period":"2025-12-31","value":247100000},{"period":"2024-12-31","value":418300000},{"period":"2023-12-31","value":206300000},{"period":"2022-12-31","value":4600000}],"eps":3.48,"epsHistory":[{"period":"2025-12-31","value":3.48},{"period":"2024-12-31","value":5.78},{"period":"2023-12-31","value":2.94},{"period":"2022-12-31","value":0.07}],"cash":907200000,"cashHistory":[{"period":"2025-12-31","value":716100000},{"period":"2024-12-31","value":953300000},{"period":"2023-12-31","value":704200000},{"period":"2022-12-31","value":674200000}],"totalAssets":3190400000,"totalLiabilities":1675100000,"totalDebt":949200000,"equity":1515300000,"operatingCashflow":569300000,"operatingCashflowHistory":[{"period":"2025-12-31","value":569300000},{"period":"2024-12-31","value":430200000},{"period":"2023-12-31","value":145700000},{"period":"2022-12-31","value":119000000}],"capex":-219400000,"capexHistory":[{"period":"2025-12-31","value":-219400000},{"period":"2024-12-31","value":-134000000},{"period":"2023-12-31","value":-109200000},{"period":"2022-12-31","value":-157300000}],"freeCashflow":349900000,"dividendsPaid":null,"buybacks":-59600000,"employees":5400,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":317200000,"ebit":127700000,"ebitda":153900000,"period":"2026-03-31","revenue":761700000,"epsBasic":1.3,"netIncome":91100000,"rdExpense":89700000,"epsDiluted":1.3,"grossProfit":529100000,"operatingIncome":122200000},{"sga":331400000,"ebit":155100000,"ebitda":179500000,"period":"2025-12-31","revenue":783800000,"epsBasic":1.44,"netIncome":101600000,"rdExpense":90900000,"epsDiluted":1.44,"grossProfit":568600000,"operatingIncome":146300000},{"sga":315200000,"ebit":138400000,"ebitda":160400000,"period":"2025-09-30","revenue":706300000,"epsBasic":1.24,"netIncome":87600000,"rdExpense":77200000,"epsDiluted":1.24,"grossProfit":510100000,"operatingIncome":117700000},{"sga":257700000,"ebit":48000000,"ebitda":70300000,"period":"2025-06-30","revenue":649100000,"epsBasic":0.32,"netIncome":22500000,"rdExpense":73400000,"epsDiluted":0.32,"grossProfit":452200000,"operatingIncome":121100000},{"sga":260700000,"ebit":57400000,"ebitda":79100000,"period":"2025-03-31","revenue":569000000,"epsBasic":0.5,"netIncome":35400000,"rdExpense":59600000,"epsDiluted":0.5,"grossProfit":409000000,"operatingIncome":88700000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":151,"previousClose":148.84,"fiftyTwoWeekHigh":354.88,"fiftyTwoWeekLow":145.59,"fiftyTwoWeekRange":"145.59 - 354.88","fiftyDayAverage":201.71,"twoHundredDayAverage":276.93,"beta":1.2,"enterpriseValue":10842953728,"forwardPE":18.7,"priceToBook":7.02,"priceToSales":3.61,"enterpriseToRevenue":3.74,"enterpriseToEbitda":18.01,"pegRatio":1.19,"ebitda":602000000,"ebitdaMargin":20.8,"freeCashflow":253375008,"operatingCashflow":619299968,"totalDebt":1014000000,"debtToEquity":77.8,"currentRatio":2.49,"returnOnAssets":9.7,"returnOnEquity":23,"analystRating":"1.5 - Buy","recommendationKey":"buy","numberOfAnalysts":24,"targetMeanPrice":250.12,"targetHighPrice":360,"targetLowPrice":175,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.3,"institutionHeldPercent":101.9,"sharesOutstanding":69264674,"floatShares":68974455,"sharesShort":2968238,"shortRatio":2.82,"shortPercentOfFloat":4.3,"epsTrailing":4.29,"epsForward":8.06,"revenuePerShare":41.28,"bookValue":21.53,"officers":[{"age":54,"name":"Ms. Ashley A. McEvoy","title":"CEO, President & Director"},{"age":52,"name":"Ms. Flavia H. Pease","title":"Executive VP & CFO"},{"age":42,"name":"Mr. Eric  Benjamin","title":"Executive VP & COO"},{"age":65,"name":"Mr. John Wodick Kapples J.D.","title":"Senior VP & General Counsel"},{"age":48,"name":"Mr. Prem  Singh","title":"Senior Vice President of Global Operations"},{"age":null,"name":"Mr. Amit  Guliani","title":"Senior VP & CTO"},{"age":null,"name":"Ms. Clare  Trachtman","title":"Vice President of Investor Relations"},{"age":null,"name":"Mr. Chuck  Medovich","title":"Senior VP and Chief Quality, Regulatory & Compliance Officer"}],"industry":"Medical Devices","irWebsite":"http://investor.insulet.com/index.cfm","website":"https://www.insulet.com","phone":"978 600 7000"}}